Search results for "Sarcoma"

showing 10 items of 566 documents

p16INK4A (CDKN2A) gene deletion is a frequent genetic event in synovial sarcomas.

2006

We assessed the frequency of genomic deletion of p16 INK4A (CDKN2A) in synovial sarcomas (SSs) and its possible association with immunoexpression of p16 and cyclin D1 and the Ki-67 proliferation index using dualcolor fluorescence in situ hybridization (FISH) on tissue microarray sections of 41 histologically and molecularly confirmed SSs. A heterozygous p16 INK4A gene deletion was identified in 28 (74%) of 38 cases, with 25 (89%) of them showing abnormal p16 protein expression (20 negative and 5 heterogeneous). Of 25 cases, 19 (76%) exhibiting increased cyclin D1 expression also demonstrated heterozygous p16 INK4A deletion. No significant association was observed between p16 INK4A deletion …

HeterozygoteProliferation indexTumor suppressor geneSoft Tissue NeoplasmsBiologySarcoma SynovialCyclin D1CDKN2ACyclin DCyclinsmedicineBiomarkers TumorHumansCDKN2A Gene DeletionCyclin-Dependent Kinase Inhibitor p16In Situ Hybridization FluorescenceCell Nucleusmedicine.diagnostic_testGeneral Medicinemedicine.diseaseImmunohistochemistrySynovial sarcomaKi-67 AntigenTumor progressionTissue Array AnalysisCancer researchGene DeletionFluorescence in situ hybridizationAmerican journal of clinical pathology
researchProduct

Histidine-rich glycoprotein-induced vascular normalization improves EPR-mediated drug targeting to and into tumors

2018

Tumors are characterized by leaky blood vessels, and by an abnormal and heterogeneous vascular network. These pathophysiological characteristics contribute to the enhanced permeability and retention (EPR) effect, which is one of the key rationales for developing tumor-targeted drug delivery systems. Vessel abnormality and heterogeneity, however, which typically result from excessive pro-angiogenic signaling, can also hinder efficient drug delivery to and into tumors. Using histidine-rich glycoprotein (HRG) knockout and wild type mice, and HRG-overexpressing and normal t241 fibrosarcoma cells, we evaluated the effect of genetically induced and macrophage-mediated vascular normalization on th…

Histidine-rich glycoproteinUT-Hybrid-DPharmaceutical ScienceVascular normalization02 engineering and technologyPermeabilityArticleMice03 medical and health scienceschemistry.chemical_compoundDrug Delivery Systems0302 clinical medicinePolymethacrylic AcidsCell Line TumorNeoplasmsmedicineAnimalsMethacrylamideTissue DistributionpHPMAFibrosarcomaMice Knockoutchemistry.chemical_classificationDrug CarriersProteins021001 nanoscience & nanotechnologymedicine.diseasePathophysiologyUp-RegulationMice Inbred C57BLHRGNanomedicineTumor targetingchemistryTargeted drug deliveryPermeability (electromagnetism)030220 oncology & carcinogenesisDrug deliveryDrug deliveryCancer researchEPR0210 nano-technologyGlycoprotein
researchProduct

Immunohistochemical detection of EWS and FLI-1 proteinss in Ewing sarcoma and primitive neuroectodermal tumors: comparative analysis with CD99 (MIC-2…

2001

The molecular analysis of the t(11;22) rearrangement involving EWS/FLI-1 genes is likely to be of diagnostic value in Ewing sarcoma (ES) and primitive neuroectodermal tumors (PNET). The objective of the current study was to analyze the immunohistochemical expression of the EWS and FLI-1 proteins in a group of small round-cell tumors (SRCT) to determine their specificity and relevance in their differential diagnosis. Forty-eight cases-10 conventional ES, 4 large-cell ES, 5 PNET, 9 neuroblastomas (NB), 6 undifferentiated synovial sarcomas (SS), 5 rhabdomyosarcomas (RB), 5 non-Hodgkin lymphomas (NHL), 1 round-cell liposarcoma, and 3 mesenchymal chondrosarcomas-were analyzed. Immunocytochemistr…

HistologyImmunocytochemistryCD99Sarcoma EwingLiposarcomaBiology12E7 AntigenSensitivity and SpecificityHeterogeneous-Nuclear RibonucleoproteinsPathology and Forensic Medicinechemistry.chemical_compoundAntigenAntigens CDProto-Oncogene ProteinsmedicineHumansNeuroectodermal Tumors PrimitiveProto-Oncogene Protein c-fli-1medicine.diseaseImmunohistochemistryDNA-Binding ProteinsMedical Laboratory TechnologyAntigen retrievalchemistryRibonucleoproteinsCancer researchTrans-ActivatorsImmunohistochemistrySarcomaDifferential diagnosisRNA-Binding Protein EWSCell Adhesion MoleculesApplied immunohistochemistrymolecular morphology : AIMM
researchProduct

Mutant p53 gain of function can be at the root of dedifferentiation of human osteosarcoma MG63 cells into 3AB-OS cancer stem cells

2014

Osteosarcoma is a highly metastatic tumor affecting adolescents, for which there is no second-line chemotherapy. As suggested for most tumors, its capability to overgrow is probably driven by cancer stem cells (CSCs), and finding new targets to kill CSCs may be critical for improving patient survival. TP53 is the most frequently mutated tumor suppressor gene in cancers and mutant p53 protein (mutp53) can acquire gain of function (GOF) strongly contributing to malignancy. Studies thus far have not shown p53-GOF in osteosarcoma. Here, we investigated TP53 gene status/role in 3AB-OS cells-a highly aggressive CSC line previously selected from human osteosarcoma MG63 cells-to evaluate its involv…

HistologyTumor suppressor genePhysiologyEndocrinology Diabetes and MetabolismApoptosisIn situ hybridizationBiologyTNF-Related Apoptosis-Inducing LigandCell MovementCancer stem cellCell Line TumorSettore BIO/10 - BiochimicaBiomarkers TumormedicineHumansNeoplasm Invasiveness3AB-OS cells CSCs Cancer cell dedifferentiation Cancer stem cells FISH Fluorescent in situ hybridization GOF Gain of function Human osteosarcoma MMPs Matrix metalloproteinases Mutant p53 Mutant p53 gain of function Mutp53 OS OsteosarcomaClonogenic assayTumor Stem Cell AssayCell ProliferationMembrane Potential MitochondrialOsteosarcomaCancerReceptors Death DomainCell DedifferentiationCell cyclemedicine.diseaseMolecular biologyAmino Acid SubstitutionProto-Oncogene Proteins c-bcl-2Gene Knockdown TechniquesMutationNeoplastic Stem CellsCancer researchOsteosarcomaEctopic expressionTumor Suppressor Protein p53Bone
researchProduct

Helical Tomotherapy® is a safe and feasible technique for total scalp irradiation

2017

Angiosarcoma of the scalp is a rare aggressive tumor that affects elderly patients. Chemoradiation is the treatment of choice for multicentric and extensive disease. The shape of the scalp represents a dosimetric challenge in terms of achieving a homogeneous concave dose distribution with coverage of the entire target volume and an acceptable organs-at-risk sparing. We report a case of an 81-year-old man with a multifocal angiosarcoma of the scalp treated with Helical TomoTherapy® (Accuray Inc., Sunnyvale, CA, USA) intensity modulated radiotherapy. This technique allows precise and daily verifiable coverage of the target keeping the dose to the organs at risk within the constraints.

Histologymedicine.medical_treatmentPlanning target volumeCase ReportDose distributionTomotherapylcsh:RC254-282Tomotherapy030218 nuclear medicine & medical imaging03 medical and health sciences0302 clinical medicineTomotherapy IGRT IMRT Scalp irradiation AngiosarcomamedicineAngiosarcomaAngiosarcomaIMRTIGRTImage-guided radiation therapyExtensive Diseaseintegumentary systembusiness.industrylcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensmedicine.anatomical_structureOncologyHomogeneous030220 oncology & carcinogenesisScalpScalp irradiationNuclear medicinebusinessRare Tumors
researchProduct

Human osteosarcoma 3AB-OS cancer stem cells is a model to study microRNA-29b-1 involvement in self-renewal and fate decisions of stem cells

2014

Human osteosarcoma 3AB-OS cancer stem cells microRNA-29b-1 self-renewal
researchProduct

Effects of tumor necrosis factor-alpha on tumor blood flow and hyperthermic treatment.

1989

The impact of recombinant human tumor necrosis factor-alpha (rhTNF-alpha), given alone or in combination with local hyperthermia, on perfusion and growth of a moderately rhTNF-alpha-sensitive rat tumor (DS-carcinosarcoma) was investigated. DS-carcinosarcomas were implanted into the hind foot dorsum of Sprague-Dawley rats. Tumor blood flow (TBF) was measured with the krypton-85 clearance technique. Treatment with either tumor necrosis factor-alpha (0.1-1.0 mg/kg) or hyperthermia (43.3 and 44.3 degrees C, 40 min) can decrease the perfusion of malignant tumors. The TBF reduction was fully established 2 h after rhTNF-alpha injection and lasted for at least 4 h. The application of local hyperthe…

HyperthermiaCancer ResearchNecrosisSoft Tissue NeoplasmsPharmacologyCarcinosarcomaTumor perfusionmedicineAnimalsTumor growthTumor necrosis factor αbusiness.industryTumor Necrosis Factor-alphaRats Inbred StrainsHematologyBlood flowHyperthermia Inducedmedicine.diseaseCombined Modality TherapyRecombinant ProteinsRatsOncologyRegional Blood FlowImmunologyTumor necrosis factor alphamedicine.symptombusinessPerfusionCell DivisionNeoplasm TransplantationOnkologie
researchProduct

Hyperlactacidaemia in isolated hyperthermic perfusion of tumour bearing rat limbs: a study of feasibility using a novel infusion solution.

1999

In a methodological study the applicability of hyperlactacidaemia in isolated hyperthermic perfusion of tumour-bearing rat limbs was investigated.In 50 Sprague Dawley rats, DS-sarcoma growth was initiated on the right food dorsum by subcutaneous injection of 0.5 ml ascites cells. In the anaesthetized animals isolated limb perfusion was performed under steady state conditions for 60min using a miniature equipment. Thereafter tumour volume was measured daily. (a) Investigation of feasability: 40 rats were allocated to four groups. Group I: Normothermic perfusion at 38 degrees C, n = 10; Group II: Hyperthermic perfusion at 40-41 degrees C, n = 10; Group III: Normothermic perfusion at 38 degree…

HyperthermiaCancer ResearchPathologymedicine.medical_specialtyPhysiologyHyperthermic perfusionRats Sprague-DawleySubcutaneous injectionPhysiology (medical)AscitesmedicineSprague dawley ratsAnimalsImmunologic FactorsLactic AcidInfusion solutionbusiness.industryExtremitiesHyperthermia Inducedmedicine.diseaseRatsAnesthesiaChemotherapy Cancer Regional PerfusionFeasibility StudiesMethodological studyFemaleSarcoma Experimentalmedicine.symptombusinessPerfusionInternational journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group
researchProduct

Circulatory and metabolic responses of malignant tumors during localized hyperthermia

1980

The effect of localized hyperthermia on the circulatory responses and on the oxygen and glucose supply has been evaluated in tissue-isolated rat tumors utilizing an in situ perfusion system. On the average, localized hyperthermia caused a significant increase in total tumor blood flow after raising of the mean tumor temperature from 37 degrees C to 39.5 degrees C. At higher temperatures (42 degrees C) total tumor blood flow decreased to a level somewhat below the flow during normothermia. However, there were great interindividual differences in the response of blood flow to temperature. The changes in blood flow were paralleled by variations of the O2-consumption and of the glucose uptake o…

HyperthermiaCancer Researchmedicine.medical_specialtyHot TemperatureGlucose uptakeVasodilationBiologyMicrocirculationOxygen ConsumptionCarcinosarcomaInternal medicinemedicineAnimalsGeneral MedicineBlood flowmedicine.diseaseKidney NeoplasmsRatsRed blood cellGlucosemedicine.anatomical_structureEndocrinologyOncologyRegional Blood FlowAnesthesiaCirculatory systemVascular resistanceVascular ResistanceSarcoma ExperimentalNeoplasm TransplantationJournal of Cancer Research and Clinical Oncology
researchProduct

In vivo targets of recombinant human tumour necrosis factor-α: blood flow, oxygen consumption and growth of isotransplanted rat tumours

1989

The impact of recombinant human tumour necrosis factor-alpha (1 microgram kg-1 to 1 mg kg-1; 6.6 x 10(6) U mg protein-1) on blood flow, oxygen consumption and growth of a moderately TNF-sensitive rat tumour (DS-carcinosarcoma) was studied. Tumour growth was stimulated at low TNF doses (1 and 10 micrograms kg-1) and significantly retarded at higher TNF dose levels (0.1 and 1 mg kg-1). Growth changes were concomitant with variations in oxygen consumption, lactate release and acidification of the metabolic micromilieu. Both single and repeated application of low TNF doses (1-10 micrograms kg-1 i.v.) increased tumour perfusion whereas single administration of high TNF dose levels (0.1-1 mg kg-1…

HyperthermiaCancer Researchmedicine.medical_specialtyNecrosismedicine.medical_treatmentBiologyOxygen ConsumptionCarcinosarcomaIn vivoInternal medicinemedicineAnimalsChemotherapyTumor Necrosis Factor-alphaCell growthAscitesRats Inbred StrainsBlood flowmedicine.diseaseRecombinant ProteinsRatsEndocrinologyOncologyRegional Blood FlowTumor necrosis factor alphamedicine.symptomPerfusionNeoplasm TransplantationResearch ArticleBritish Journal of Cancer
researchProduct